Comparison of efficacy ofSalmonella typhimuriumA1-R and chemotherapy on stem-like and non-stem human pancreatic cancer cells

Salmonella typhimurium 0301 basic medicine Nude pancreatic cancer Drug Resistance Mice, Nude Antineoplastic Agents GFP confocal microscopy Cell Line Pancreatic Cancer Mice 03 medical and health sciences Rare Diseases amino acid auxotrophy fluorescence imaging Stem Cell Research - Nonembryonic - Human Cell Line, Tumor Antineoplastic Combined Chemotherapy Protocols RFP Animals Humans Cancer Microscopy Tumor Microscopy, Confocal chemoresistance Stem Cell Research Xenograft Model Antitumor Assays 3. Good health stem cell Pancreatic Neoplasms Orphan Drug selective tumor targeting Treatment Outcome Drug Resistance, Neoplasm Confocal Neoplastic Stem Cells Neoplasm Stem Cell Research - Nonembryonic - Non-Human Biochemistry and Cell Biology Digestive Diseases Developmental Biology
DOI: 10.4161/cc.25872 Publication Date: 2013-08-21T20:40:11Z
ABSTRACT
The XPA1 human pancreatic cancer cell line is dimorphic, with spindle stem-like cells and round non-stem cells. We report here the in vitro IC 50 values of stem-like and non-stem XPA1 human pancreatic cells cells for: (1) 5-fluorouracil (5-FU), (2) cisplatinum (CDDP), (3) gemcitabine (GEM), and (4) tumor-targeting Salmonella typhimurium A1-R (A1-R). IC 50 values of stem-like XPA1 cells were significantly higher than those of non-stem XPA1 cells for 5-FU (P = 0.007) and CDDP (P = 0.012). In contrast, there was no difference between the efficacy of A1-R on stem-like and non-stem XPA1 cells. In vivo, 5-FU and A1-R significantly reduced the tumor weight of non-stem XPA1 cells (5-FU; P = 0.028; A1-R; P = 0.011). In contrast, only A1-R significantly reduced tumor weight of stem-like XPA1 cells (P = 0.012). The combination A1-R with 5-FU improved the antitumor efficacy compared with 5-FU monotherapy on the stem-like cells (P = 0.004). The results of the present report indicate A1-R is a promising therapy for chemo-resistant pancreatic cancer stem-like cells.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (22)
CITATIONS (74)